MedTrace Logo

MK0524A Phase IIb Study (0524A-011)(COMPLETED)

NCT00536237 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2015-08-25

No results posted yet for this study

Summary

Part A: This study will determine that MK0524 is well tolerated and does not effect lipids and blood glucose when given alone.

Part B: Determine dose ranges for MK0524 and MK0524 plus Niaspan(R) on the effects of lipids and blood glucose.

Conditions

  • Flushing

Interventions

DRUG

Comparator: niacin / Duration of Treatment: 17 Weeks

DRUG

MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks

DRUG

Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2005-02-28
Completion
2006-12-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00536237 on ClinicalTrials.gov